What biosimilars have been approved in the United States?
Biosimilar Comparable in Safety, Efficacy to Tysabri in Phase 3 Trial
Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: Primary data from the Phase III Antelope study (P6-4.003)
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations
Guidelines for Approval of DMT Biosimilars, Use In Europe Drafted
Biosimilar to Tysabri for Relapsing-Remitting MS Is On Its Way
Eye on Pharma: Natalizumab Injunction; Oral Ustekinumab Development; New Study for Secukinumab Biosimilar
